Efficacy and safety of evolocumab in chinese patients with primary hypercholesterolemia and mixed dyslipidemia: primary results of the Hua Tuo _ clinical trial

Abstract

Background and Aims : The prevalence of dyslipidemia in China is approximately 40%, and many patients treated with lipid-lowering therapies fail to achieve LDL-C goals. This study evaluated the effect of evolocumab on LDL-C levels in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia with baseline LDL-C levels of ≥80 mg/dL or ≥130 mg/dL despite optimal stable statin therapy.